Hester Biosciences Limited has informed the Exchange regarding a press release dated January 24, 2026, titled "20260124 Press Release - Hester receives manufacturing license for Inactivated Avian Influenza Vaccine for poultry".
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences has received a manufacturing license for its Inactivated Avian Influenza (bird flu) Vaccine for poultry, as announced via a press release dated January 24, 2026. Avian influenza has been a growing concern among poultry farmers globally, and this license allows the company to commercially manufacture and supply the vaccine in India. The company already has a strong presence in animal vaccines, and this addition strengthens its poultry health portfolio. Specific commercial details such as production capacity, launch timeline, and pricing have not been disclosed in this filing.
This is a positive development for Hester Biosciences as it opens a new revenue stream in a high-demand segment. Bird flu outbreaks have been recurring in India, creating strong market potential for an approved vaccine, which could boost future earnings and investor sentiment.